The online hub for digital CME and CE courses
The ONA Forum consultants answer your questions
View articles about patient-focused care
Time to tumor growth proved to be the best metric for predicting overall survival in persons with metastatic colorectal cancer on bevacizumab.
Computerized tomography adds to lactate dehydrogenase (LDH) levels in predicting survival among persons with metastatic melanoma on bevacizumab.
Combining the antiangiogenic bevacizumab with the kinase inhibitor dasatinib stopped glioblastoma metastasis after shrinking the tumors.
Bevacizumab plus chemotherapy improved survival in women with advanced, recurrent, or persistent cervical cancer, according to interim findings.
The FDA has approved bevacizumab combined with other chemotherapy when metastatic colorectal cancer has progressed after first-line bevacizumab.
Positron emission tomography (PET) can non-invasively predict how much of a cancer-killing drug is absorbed by a tumor. This preliminary study, conducted in lung cancer patients, found that less than 1% of docetaxel is absorbed by the tumors.
Positron emission tomography (PET) can non-invasively predict how much of a cancer-killing drug is absorbed by a tumor. This preliminary study, conducted in lung cancer patients, found that less than 1% of docetaxel is absorbed by the tumors.
Patients with low levels of the protein VEGF165b who were treated with bevacizumab (Avastin) survived 3 months longer without their colorectal cancer progressing compared with patients not treated with the drug.
June 01, 2012
An increased risk of coronary artery stenosis in cancer survivors may be a long-term posttreatment effect of chest radiotherapy.
April 17, 2012
New research is showing that sequence and timing have significant impact on the efficacy of therapeutic regimens that include bevacizumab.
The use of bevacizumab (Avastin) improved progression-free survival in women with ovarian cancer, particularly those at high risk for disease progression.
The FDA has revoked its approval of the breast cancer indication for Avastin (bevacizumab). The anti-angiogenic therapy remains indicated for some colorectal, lung, brain, and kidney cancers.
The FDA has announced labeling changes for bevacizumab (Avastin), indicated for the treatment of glioblastoma and colorectal, breast, kidney, and nonsquamous non-small cell lung cancers.
The Advisor Forum panel answers nurses' questions about patient care, treatment regimens, and oncology nursing.
The Clinical Practice Guidelines in Oncology for Breast Cancer, published by NCCN, have been updated to affirm the existing recommendation regarding the use of bevacizumab (Avastin) for the treatment of metastatic breast cancer.
Treating patients with the recombinant monoclonal antibody bevacizumab carries a significant risk of venous thromboembolism (VTE), a meta-analysis has shown.
Adding cetuximab to the treatment regimen of patients with metastatic colorectal cancer (CRC) results in worse outcomes, a controlled trial has shown.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |
